drugset / Trial / NCT01438424

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

NCT01438424

Phase 2 Completed 1053 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.

Timeline

Start
2001-01
Primary completion
2009-12
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 1 mg Oral
Background Lamivudine Other / unclassified 100 mg Oral